What is TOMI Environmental's latest dividend and current dividend yield?

Did TOMI Environmental beat or miss consensus estimates last quarter?

What factors drove the changes in TOMI Environmental's revenue and profit?

What were the key takeaways from TOMI Environmental's earnings call?

What does TOMI Environmental do and what are its main business segments?

What is the market's earnings forecast for TOMI Environmental next quarter?

What were the key takeaways from TOMI Environmental’s earnings call?

What guidance did TOMI Environmental's management provide for the next earnings period?

- **Revenue Recovery**: Q3 2025 revenue up 95% sequentially to $2 million, driven by BIT Solution sales (21% YTD growth) and equipment purchases.
- **FDA Breakthrough**: Hydrogen peroxide approval for food safety opens $3+ billion RTE market; direct food surface disinfection now possible.
- **Strategic Capital**: $20M equity purchase agreement provides funding flexibility for 2026 growth initiatives.
- **Key Wins**: New customers include Bausch & Lomb, Nestle, and major pharma companies; $3M custom automation pipeline.
- **Gross Margin Resilience**: 61% gross margin maintained despite 24% YoY revenue decline.

**【CEO Summary Section】**
- Q3 2025 revenue reached $2 million, a 95% sequential increase driven by recurring BIT Solution sales (up 21% YTD) and capital equipment purchases from service providers.
- Sales backlog grew to $1.3 million by end of October, with $3 million in pending SteraMist Integration Contracts expected to close by year-end.
- FDA approval of hydrogen peroxide for food safety opens new markets, including RTE (ready-to-eat) food processing and transportation.
- Strategic partnership with Hudson Global Ventures provides $20 million equity purchase flexibility for scaling initiatives.

**【CFO Financial Commentary】**
- Q3 2025 revenue ($2 million) declined 24% YoY due to delayed iHP services from a key customer, but year-to-date service demand rose 35% in life sciences/food safety.
- Gross margin remained strong at 61%, while operating loss was $320,000 vs. $149 million profit in Q3 2024.
- Cash reserves of $190,000 and working capital of $2.5 million support near-term operations.

**【COO Business Highlights】**
- New customers include Bausch & Lomb (eye health) and Nestle (food safety), with SteraMist deployments across 20+ countries.
- FDA approval enables direct food surface disinfection, targeting RTE food processing, packaging, and transportation.
- Pharmaceutical industry adoption growing with SteraMist Integrated Systems (SIS) for bioprocessing automation.
- $3 million pipeline in custom automation solutions for 2025 close.

**【Q&A Highlights】**
- **Food Safety Expansion**: FDA approval validation efforts underway with major food processors; initial focus on RTE, prepackaged meals, and transportation.
- **Military & Defense**: Engaged with U.S. military on formaldehyde replacement studies; expects 2026 deal.
- **Data Center Market**: Exploring partnerships for large-scale facility disinfection; sales team expansion planned.
- **Medical Sterilization**: Testing SteraMist as ethylene oxide alternative for medical device sterilization.
- **Operating Expenses**: Expect revenue growth to outpace expense increases, maintaining ~60% gross margin.

TOMI Environmental Solutions, Inc. (TOMZ) Q3 2025 Earnings Call Transcript

- **Service-driven growth**: Q2 service revenue up 46% YoY to $955K, with 35% quote growth.
- **Margin improvement**: Gross margin 66% (vs. 6%), reflecting high-margin service focus.
- **Pipeline strength**: $15M pipeline ($7M high-priority), $2M new contracts expected.
- **FDA progress**: 510(k) and FCN approvals nearing completion for expanded use cases.
- **Challenges**: Product revenue down 66% YoY due to deferred projects, but 2 customers re-engaging.

**【Management Opening Remarks】**
- CEO Halden Shane highlighted Q2 momentum, with $4.6M in recognized/deferred revenue and $2M in new contracts expected to close by year-end.
- Service revenue grew 33% YoY to $378K, driven by Life Sciences and Food Safety clients.
- Gross margin improved to 66% (vs. 6% prior year), reflecting higher-margin service mix.
- Open pipeline totals $15M ($7M high-priority), including $1.8M in Q2 revenue.

**【CEO Commentary】**
- Q2 revenue $1.03M (-66% YoY) due to deferred capital projects amid macro uncertainty.
- Service revenue up 46% YoY to $955K, with 35% increase in service quotes.
- Key wins: NASA project operational, $180K university SIS deal, and USDA expanded usage.
- Solution sales up 40% YTD, positioning as 'razorblade' model with high margins.

**【CFO Financial Commentary】**
- Operating loss $1.1M vs. $120K prior year, net loss $1.28M (-$0.06/share).
- Cash: $569K, working capital $2.8M, shareholders' equity $2.7M.
- Deferred revenue $700K, with 2 customers re-engaging for Q1'26 projects.

**【COO Business Highlights】**
- $2M pipeline in custom contracts, $105K-$1.8M bids across SIS/CES/Hybrid.
- 35% YoY growth in service quotes, including DoD collaboration.
- International pipeline in EU/UK pending registrations, with $25K avocado sector opportunity.
- FDA FCN approval in process for food contact applications.

**【Q&A Highlights】**
- Solution sales margins >66%, driven by service mix.
- 2 customers re-engaging on deferred projects for Q1'26 delivery.
- FDA 510(k) for medical devices and FCN for food safety nearing approval.
- Exploring new uses like floriculture and material handling.

TOMI Environmental Solutions (TOMZ)-14 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Soars 42%**: Q1 2025 revenue of $1.577M driven by 200%+ growth in BIT Solutions and 56% jump in service revenue.
- **BIT Solution Explosion**: Year-to-date BIT sales up 169%, with Q1 solution sales tripling YoY.
- **Strategic Wins**: $1.6M sales backlog includes $170K eye health order and $288K medical device contract; aquaculture expansion via Algafeed partnership.
- **Government & Food Safety Momentum**: Increased government testing and food safety inquiries position SteraMist as critical disinfection tool.
- **SIS & CES Expansion**: SIS-SA standalone units target hospitals; CES pipeline of $2M reflects growing demand for custom sterilization solutions.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue reached $1.577 million, a 42% year-over-year increase, driven by BIT Solution sales (+200%), service revenue (+56%), and product sales (+35%).
- **BIT Solution Surge**: Year-to-date BIT Solution sales surged 169%, with Q1 solution sales up 197% YoY.
- **New Customers & Partnerships**: Secured $170,000 order from an American-Canadian eye health company and $288,000 contract for heart monitoring device decontamination. Expanded into aquaculture via Algafeed partnership.
- **Financial Health**: Gross margin remained stable at 60.4%, operating loss improved to $754,000 (vs. $1.226M YoY), and net loss narrowed to $0.01 per share.
- **Backlog Expansion**: Open sales log rose to $1.6 million (from $877,000 at end-2024), driven by iHP Corporate Services and Custom Engineered Systems (CES).

**【Q&A Key Highlights】**
- **Tariffs & Trade Policy**: Minor 15% South Korea tariff issue resolved with distributor split; no material impact on international sales.
- **Government Relations**: Increased government testing/studies on SteraMist; no adverse effects from budget cuts.
- **Food Safety Growth**: Large manufacturers and universities requesting quotes, with food safety expected to surpass life sciences as key market.
- **Ethylene Oxide Replacement**: In talks with companies to replace EO with SteraMist; heart monitor decontamination project not yet an EO replacement but a protocol development win.
- **SIS System Clarification**: SIS-SA integrates cold plasma technology into standalone units, suitable for small-area sterilization (e.g., hospitals).
- **Education Initiative**: SteraMist Pro Certified Program offers LMS-based training for customers, distributors, and service providers.
- **CES Pipeline**: $2 million in active CES bids across five opportunities; hybrid systems range from $150,000 to $800,000 per installation.


TOMI Environmental Solutions, Inc. (TOMZ) Q1 2025 Earnings Call Transcript

- **Revenue Resilience**: FY2024 GAAP revenue up 5% to $7.7 million, with Non-GAAP at $8 million, driven by mobile systems and iHP services.
- **Pipeline Strength**: $3.7 million CES pipeline and $1 million+ SIS pipeline, with 2025 deal closures targeting $1.4 million.
- **Margin Focus**: Non-GAAP gross margin stable at 60%, with cost reductions (R&D -41%, sales -17%) supporting efficiency.
- **Growth Catalysts**: 200% YoY BIT Solution growth, NASA partnership, and $3.5 million capital raise to fuel 2025 expansion.
- **Key Risks**: Regulatory delays (FDA 1% H2O2 label), but 2025 cash flow positive with disciplined execution.


**【CEO Summary Section】**
- **Revenue Growth**: FY2024 GAAP revenue reached $7.7 million, up 5% YoY, driven by mobile systems and iHP corporate services. Non-GAAP revenue was $8 million, reflecting a 6% increase.
- **Strategic Wins**: Secured $3.7 million in CES deals across 46 projects, with 12 active and 5 expected to close in 2025. SIS pipeline exceeds $1 million, with $575k in Q1 2025 sales.
- **Market Expansion**: Established 13 new distribution partners in 2024, generating $930k in sales. Key wins include Malaysia (BIBO chamber decontamination) and India (genetic drug manufacturing).
- **Service Growth**: iHP services saw a 42% Q1 2025 YoY increase, with Enviro-Mist investing $1 million in equipment for West Coast deployment.
- **Cost Management**: Reduced R&D expenses by 41%, sales commissions by 17%, and consulting costs by 20%. Q3 2024 achieved positive cash flow, targeting sustainable cash flow in 2025.

**【CFO Financial Commentary】**
- **GAAP Metrics**: FY2024 GAAP net loss was $4.5 million ($0.22/share), up from $3.4 million ($0.17/share) in 2023. GAAP gross margin was 46%, down from 58% due to inventory reserves.
- **Non-GAAP Metrics**: Non-GAAP operating loss improved to $1.7 million ($0.10/share) from $2.8 million ($0.14/share). Non-GAAP gross margin remained stable at 60%.
- **Cash Position**: Ended 2024 with $665k cash and $3.8 million working capital. 2025 plans include $3.5 million convertible note raise to support growth.

**【Q&A Key Highlights】**
- **2025 Guidance**: Management expects pipeline of $3.2 million to drive revenue, with focus on SIS and CES projects. BIT Solution sales up 200% YoY organically.
- **Margins**: Razor/razor-blade model margins expected to improve as high-margin BIT Solutions (e.g., 55-gallon drums) grow.
- **Tariffs & FDA**: No immediate tariff impact; FDA 1% H2O2 label for food applications uncertain due to regulatory changes.
- **Partnerships**: NASA collaboration to expand SteraMistX cloud; PBSC Biotech (Singapore) and Sterile Grow (cannabis) partnerships advancing.
- **Risk Mitigation**: Reduced returns in 2025; one-time 2024 returns ($800k) partially offset by $180k upsell in Q1 2025.


Actual					-0.03	-0.08	-0.03	-0.04	-0.03	-0.04	-0.06	0	-0.05	-0.06	-0.07	0	0	-0.05	-0.01	-0.06	-0.02
Forecast						-0.02	-0.06	-0.03	-0.02	0	-0.02	0.01	-0.02	-0.01	-0.02	-0.04	0	0.01	-0.05	-0.03	-0.01	-0.02
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	-300.00%	+50.00%	-33.33%	-50.00%	0.00%	-200.00%	-100.00%	-150.00%	-500.00%	-250.00%	+100.00%	0.00%	-600.00%	+80.00%	-100.00%	-100.00%	0.00%

Actual	--	--	--	--	2.20M	2.01M	2.31M	1.46M	1.76M	2.81M	1.58M	2.77M	1.47M	1.53M	1.11M	3.01M	2.54M	1.30M	1.58M	1.03M	2.01M	--
Forecast	--	--	--	--	--	2.70M	1.99M	2.57M	3.23M	2.97M	2.90M	4.00M	2.85M	2.86M	2.60M	2.83M	3.87M	3.40M	1.54M	1.80M	2.74M	2.31M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	-25.55%	+15.83%	-43.28%	-45.44%	-5.46%	-45.44%	-30.63%	-48.37%	-46.62%	-57.15%	+6.37%	-34.29%	-61.88%	+2.57%	-42.72%	-26.59%	0.00%

TOMZ

TOMZ fundamentals

TOMZ Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

TOMZ

TOMZ fundamentals

TOMZ Q4 2025 Earnings Preview

Earnings Call

TOMZ Earnings Call Summary for Q4/2025Upcoming4:30 PM on Mar 31, 2026

TOMZ Earnings Call Summary for Q3/20254:30 PM on Nov 14, 2025

TOMZ Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

TOMZ Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

TOMZ Earnings Call Summary for Q4/20244:30 PM on Apr 14, 2025

You can ask Aime